LeMaitre Vascular, Inc. — 2015 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2015; this is an annual report, not a standalone fourth-quarter filing. LeMaitre develops, manufactures, and sells medical devices for peripheral vascular disease, primarily to hospitals through a direct sales force. About 92% of 2015 sales came from territories with direct representatives; 42% came from outside the United States. Lower-extremity products represented 53% of revenue and carotid products 29%.
Financial results and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Net sales | $78.4 million | $71.1 million |
| Gross profit / margin | $54.2 million / 69.1% | $48.4 million / 68.1% |
| Operating income | $11.5 million | $6.3 million |
| Net income | $7.8 million | $3.9 million |
| Diluted EPS | $0.42 | $0.23 |
| Operating cash flow | $11.4 million | $5.5 million |
| Cash and cash equivalents at year-end | $27.5 million | $18.7 million |
Current assets were $58.2 million and current liabilities $10.4 million at year-end 2015. Total liabilities were $12.8 million; the filing reports no outstanding debt at year-end. Management said available cash and expected operating resources should cover anticipated requirements for at least 12 months. Investing activities used $3.5 million; financing activities provided $1.1 million. Dividends declared were $0.16 per share in 2015, up from $0.14.
Changes versus prior year
- Sales grew 10%; acquired product lines contributed 4.5% to growth. Higher sales of biologic patches, valvulotomes, and biosynthetic grafts were partly offset by lower occlusion-catheter sales.
- Gross margin rose 1.0 percentage point, helped by pricing—particularly the 1.5mm HYDRO valvulotome—and manufacturing efficiencies; foreign exchange and lower-margin international mix partly offset gains.
- Operating income rose about 82% and net income nearly doubled. R&D expense increased 17% to $5.5 million; operating expenses included a $0.36 million gain on the UnBalloon divestiture. No restructuring charge was recorded in 2015, compared with $0.53 million in 2014.
- The stronger U.S. dollar was estimated to reduce 2015 revenue by $5.6 million, gross margin by 1.7 percentage points, and operating income by $2.8 million versus 2014 exchange rates.
- Fourth-quarter 2015 sales were $20.5 million, operating income $3.1 million, net income $2.5 million, and diluted EPS $0.13.
Outlook, risks, and unusual items
- No quantified sales or earnings guidance was provided. Management planned to expand the sales force in 2016 and expected related sales and marketing expense to increase; China expansion was also expected to raise selling costs. Management expected the effective tax rate to rise in 2016.
- The medical-device excise tax was about $0.7 million in 2015; legislation suspended it for 2016 and 2017.
- A material weakness in revenue-recognition controls concerned validation of pricing terms and conditions, including whether sale prices were fixed or determinable at shipment. Management was implementing remediation. The weakness had not caused a reported restatement or adjustment; the auditor issued an adverse opinion on internal control, while giving an unqualified opinion on the financial statements.
- Key risks include continued movement from open surgery to endovascular procedures, competition and pricing pressure, foreign-exchange exposure, reliance on single- or limited-source suppliers, regulatory and reimbursement changes, and delayed collections from certain European public-sector customers. Italy and Spain receivables were $1.0 million and $0.5 million, respectively.
- 2015 transactions included acquisition of Tru-Incise valvulotome rights for non-U.S. sales and sale of the UnBalloon product line, generating a $0.36 million gain. The company expected to complete Tru-Incise manufacturing transfer to Burlington in 2016.
Investor verification priorities
- Track remediation and testing of the revenue-recognition material weakness, and any subsequent control or reporting developments.
- Assess the quality and durability of growth, including pricing contribution, acquired-product sales, and lower-margin geographic mix.
- Monitor currency effects, sales-force expansion costs, and the expected 2016 tax-rate increase.
- Review cash conversion, working-capital movements, receivables collection in Italy and Spain, and acquisition-related commitments.
- Verify progress on manufacturing transfer, supplier continuity, and regulatory or reimbursement developments affecting the product portfolio.